NASDAQ:ZBIO ProShares UltraPro Short Nasdaq Biotechnology (ZBIO) Price, Holdings, & News → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free ZBIO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.09▼$10.0950-Day Range$10.02▼$10.0952-Week Range$8.28▼$18.64VolumeN/AAverage Volume32,378 shsMarket Capitalization$2.52 millionAssets Under Management$2.85 millionDividend Yield0.30%Net Expense Ratio0.95% Stock AnalysisStock Analysis Get ProShares UltraPro Short Nasdaq Biotechnology alerts: Email Address Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here ZBIO ETF News HeadlinesFebruary 25, 2023 | benzinga.comBullfrog AI Hldgs Stock (NASDAQ:BFRG), Quotes and News SummaryFebruary 16, 2023 | morningstar.comProFunds Short NASDAQ-100 SvcMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…September 17, 2022 | wsj.comNasdaq Biotechnology Index NBIAugust 23, 2022 | ca.finance.yahoo.comProShares UltraPro Short Nasdaq Biotechnology (ZBIO)See More Headlines Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares UltraPro Short Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerProShares Fund NameProShares UltraPro Short Nasdaq Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:ZBIO Inception Date6/22/2015 Fund ManagerMichael Neches, Tarak Dave WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNASDAQ Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings0 Fund Statistics Assets Under Management$2.85 million Average Daily Volume$25,501.70 Discount/Premium0.00% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Miscellaneous Outstanding Shares250,000BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Ad DTImy top trade on these 9 tickersThis indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.Click Here for this Powerful Workshop ProShares UltraPro Short Nasdaq Biotechnology ExpensesTypeZBIOHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.57%0.54%0.48%0.51%Other Expenses1.02%0.40%0.54%0.32%0.58%Total Expense1.77%0.72%0.70%0.57%0.70%Fee Waiver-0.82%-0.53%-0.54%-0.20%-0.56%Net Expense0.95%0.61%0.60%0.54%0.58% ProShares UltraPro Short Nasdaq Biotechnology (ZBIO)Full Holdings Details Similar ETFsProShares UltraShort Nasdaq BiotechnologyNASDAQ:BISJPMorgan Healthcare Leaders ETFNASDAQ:JDOCHorizon Kinetics Medical ETFNASDAQ:MEDXFirst Trust Nasdaq Pharmaceuticals ETFNASDAQ:FTXHInvesco Nasdaq Biotechnology ETFNASDAQ:IBBQ ZBIO ETF - Frequently Asked Questions What does ZBIO invest in? ProShares UltraPro Short Nasdaq Biotechnology is a equity fund issued by ProShares. ZBIO focuses on health care investments and follows the NASDAQ Biotechnology Index. The fund's investments total to approximately $2.85 million assets under management. What is the management fee for ProShares UltraPro Short Nasdaq Biotechnology? ProShares UltraPro Short Nasdaq Biotechnology's management fee is 0.75% and has other expenses of 1.02%. However, ZBIO has a fee waiver of -0.82% to reimburse the expenses. The net expense ratio for ZBIO is 0.95%. What other stocks do shareholders of ProShares UltraPro Short Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProShares UltraPro Short Nasdaq Biotechnology investors own include ProShares UltraPro Short QQQ (SQQQ), ProShares UltraPro QQQ (TQQQ), Immunomedics (IMMU), Direxion Daily S&P Biotech Bear 3x Shares (LABD), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Direxion Daily Semiconductors Bull 3x Shares (SOXL), Direxion Daily Small Cap Bull 3X Shares (TNA), Direxion Daily Small Cap Bear 3X Shares (TZA), Verizon Communications (VZ) and Eaton Vance Tax-Managed Buy-Write Opportunities Fund (ETV). This page (NASDAQ:ZBIO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThe 3rd Revolution in WarfareWeiss RatingsBill Ackman’s 2024 warningPorter & CompanyUrgent: Protect Your Investments from a Chinese InvasionBehind the MarketsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares UltraPro Short Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.